Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

China Internet Weekly (8Aug2022): Tencent, NTES, Kuaishou, Autohome

Tencent (700 HK) Pre-Earnings: Still to Be Slow in 2Q22, But Price Overly Impacted

Tencent/Netease: Under Pressure with No Game Approval in July

Tencent/Netease: Smell of Common Prosperity in June Game Approval

Tencent/Netease: China Game Approval Resumption Is a Relieve, but Not Out of Tunnel

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>China just announced game approval for August batch. More games were approved in August compared to July and June.</li>
<li>Pace of China game approval continued to pick up albeit at a much slower pace than pre-tightening.</li>
<li>Both Tencent and Netease will be under increasing pressure as the duo continue to score zero in August, making it the fourth time with no games approved since resumption . </li>
</ul>


China just announced game approval for August batch. More games were approved in August compared to July and June.
Pace of China game approval continued to pick up albeit at a much slower pace than pre-tightening.
Both Tencent and Netease will be under increasing pressure as the duo continue to score zero in August, making it the fourth time with no games approved since resumption . 


Tencent/Netease: Increasing Pressure with Zero Approval in August Batch & Thoughts on Trading